Figure 6: Landmark analysis at six months; 100%, horizontally-stacked, utilization-adjusted bar charts of efficacy and safety limited to a follow-up period of six months. The vertical height of each bar is proportional to the number of patients in the cohort for 4 years of follow up. The number of patients experiencing the events of interest are represented as proportions within each bar. Event proportions are unadjusted for confounding factors
Drug A: Apixaban, Drug B: Rivaroxaban, Drug C: Warfarin